Arbli Generic: When Will Generic Losartan Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Arbli Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? October 2041 About 15 years away Why then?
- Has the FDA approved a generic? April 2010 16 companies approved
- When does the last patent end? October 2041 3 patents listed with the FDA
- Can you buy a generic today? Yes 65 companies list one
It already is. A generic losartan potassium is listed for sale by 65 companies, so ask your pharmacy whether it can fill your prescription with one.
Why October 2041?
It is when Arbli’s patents 11,890,273, 12,156,869 and 12,605,365 end. They cover the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them. We rate it toss-up: still unsettled. Just as likely to slip as to hold.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Arbli, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Arbli by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Toss-up Still unsettled. Just as likely to slip as to hold.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2025 March 2025 FDA Orange Book
- Patents listed 3 last runs to October 2041 FDA Orange Book
- Generics FDA-approved 16 companies, the first approved April 2010 FDA Orange Book
- Medicare Part D spent $13.6K in 2025, for 16 people CMS Part D Spending by Drug
- Medicaid prescriptions 52 in the last four reported quarters, $27.2K CMS Medicaid drug utilization, to Q1 2026
Arbli’s Road to a Generic
Arbli has had the market to itself since the FDA approved it in March 2025 (Scienture LLC). Its 3 listed patents run to October 2041.
The first generic of Arbli is expected in October 2041.
Why that month: patents 11,890,273, 12,156,869 and 12,605,365, on the product’s formulation and a way of using it, end then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Arbli Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Arbli’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patents 11,890,273, 12,156,869 and 12,605,365, which end in October 2041, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 11,890,273 Sets the expected month of generic availability | The product’s formulation | October 2041 | Active |
| 12,156,869 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-4158, U-4159, U-4160) | October 2041 | Active |
| 12,605,365 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-4159, U-4160) | October 2041 | Active |
Source: FDA Orange Book, application 218772. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Losartan Potassium
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No application count is on record for Arbli, but the FDA has already approved 16 companies (step 2), and every approval starts with an application.
Approved by the FDA
The FDA has approved generic versions from 16 companies, the first in April 2010. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic losartan potassium is listed for sale by 65 companies. Ask your pharmacy whether it can fill your prescription with it.
A-S Medication Solutions, AiPing Pharmaceutical, Inc., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, American Health Packaging, Aphena Pharma Solutions - Tennessee, LLC and 34 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Aiping Pharmaceutical Inc | October 2010 | 25MG, 50MG, 100MG | AB |
| Alembic Pharmaceuticals Ltd | October 2010 | 25MG, 50MG, 100MG | AB |
| Aurobindo Pharma Ltd | October 2010 | 25MG, 50MG, 100MG | AB |
| Chartwell Rx Sciences LLC | October 2010 | 25MG, 50MG, 100MG | AB |
| Lupin Ltd | October 2010 | 25MG, 50MG, 100MG | AB |
| Strides Pharma Global Pte Ltd | October 2010 | 25MG, 50MG, 100MG | AB |
| Watson Laboratories Inc | October 2010 | 25MG, 50MG, 100MG | AB |
| Zydus Pharmaceuticals USA Inc | October 2010 | 25MG, 50MG, 100MG | AB |
| Prinston Pharmaceutical Inc | June 2011 | 25MG, 50MG, 100MG | AB |
| Macleods Pharmaceuticals Ltd | May 2012 | 25MG, 50MG, 100MG | AB |
| Jubilant Cadista Pharmaceuticals Inc | September 2012 | 25MG, 50MG, 100MG | AB |
| Hetero Labs Ltd Unit V | August 2015 | 25MG, 50MG, 100MG | AB |
| Unichem Laboratories Ltd | October 2015 | 25MG, 50MG, 100MG | AB |
| Granules India Ltd | February 2023 | 25MG, 50MG, 100MG | AB |
| Msn Laboratories Private Ltd | August 2023 | 25MG, 50MG, 100MG | AB |
| Graviti Pharmaceuticals Private Ltd | September 2025 | 25MG, 50MG, 100MG | AB |
| Teva Pharmaceuticals USA Inc discontinued | April 2010 | 25MG, 50MG, 100MG | – |
| Apotex Corp discontinued | October 2010 | 25MG, 50MG, 100MG | – |
| Hikma Pharmaceuticals USA Inc discontinued | October 2010 | 25MG, 50MG, 100MG | – |
| Mylan Pharmaceuticals Inc discontinued | October 2010 | 25MG, 50MG, 100MG | – |
| Torrent Pharmaceuticals Ltd discontinued | October 2010 | 25MG, 50MG, 100MG | – |
| Micro Labs Ltd discontinued | September 2012 | 25MG, 50MG, 100MG | – |
| Ipca Laboratories Ltd discontinued | August 2013 | 25MG, 50MG, 100MG | – |
| Hisun Pharmaceutical Hangzhou Co Ltd discontinued | April 2019 | 25MG, 50MG, 100MG | – |
| Apotex Inc discontinued | June 2024 | 25MG, 50MG, 100MG | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Arbli Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Arbli, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Arbli
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Arbli, before manufacturer rebates.
- $61.9K
- January to March 2026, the latest CMS has posted
For 65 people, about $645 per prescription fill - $13.6K
- 2025, the whole year
For 16 people, about $802 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $61,896 | 65 | $644.75 |
| 2025 | $13,633 | 16 | $801.95 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Arbli only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.
Medicaid Prescriptions by Quarter
52 prescriptions in the four quarters to Q1 2026, $27.2K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 52 | $27,187 |
| Q4 2025 | 0 | $0 |
Source: CMS Medicaid State Drug Utilization Data, over Arbli’s own package codes.
Arbli Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 10MG/ML | Suspension | Oral | March 2025 | Prescription reference product |
Source: FDA Orange Book, Scienture LLC. Listed for sale today by Scienture LLC (FDA NDC Directory).
Arbli NDC Codes and Packages
Each Arbli package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 83245-0053-06 | LOSARTAN POTASSIUM 10 mg/mL suspension | bottle of 165 mL | Scienture LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Arbli’s own FDA approval (NDA 218772) are listed, never a generic. Some codes belong to companies that repackage Arbli: it is the same medicine in a different package.
What a Generic Arbli Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Arbli
Is there a generic for Arbli right now?
Yes. The FDA NDC Directory lists a generic losartan potassium from 65 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Arbli go generic?
It already has. The FDA NDC Directory lists a generic losartan potassium from 65 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic losartan potassium be the same as Arbli?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. The FDA has already approved 16 companies to make a generic, and how many of them launch decides how far the price falls.
Has the FDA approved a generic Arbli?
Yes. The FDA Orange Book lists approved generic versions from 16 companies, the first approved in April 2010: Aiping Pharmaceutical Inc, Alembic Pharmaceuticals Ltd, Aurobindo Pharma Ltd, Chartwell Rx Sciences LLC and 12 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Arbli patent expire?
The FDA Orange Book lists 3 patents for Arbli; the last runs to October 2041. The one behind the expected month is patents 11,890,273, 12,156,869 and 12,605,365, which end in October 2041. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (October 2041) weighs all of that.
Changes to This Projection
- First generic expected October 2041 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- GloperbaColchicine2027 to 2028
- Cardene IVNicardipine HydrochlorideDecember 2027
- MacrilenMacimorelin AcetateApril 2028
- TrulancePlecanatide2031 to 2032
- ZerviateCetirizine HydrochlorideJanuary 2033
- QlosiPilocarpine HydrochlorideAugust 2037
About Arbli
- Generic name losartan potassium
- How it is taken By mouth
- Company Scienture LLC
- More drugs Brand-name drugs starting with A
- Have a question? A pharmacist answers, free. Ask about Arbli
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.